Editorials

Can Large Simple Trials Help Us Understand When and How to Use Generic Drugs for Uncommon Diseases?
J.A. Molitor, D.L. Demets ........................................... 539

Quality Guidelines for Systemic Lupus Erythematosus: Slow But Steady Progress
D.J. Wallace .............................................................. 542

C’mon, CAM
R.S. Panush .............................................................. 544

The Role of Complementary and Alternative Medicine (CAM) in Rheumatology — It’s Time for Integrative Medicine
A. Michalsen .............................................................. 547

Review

Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies
I.N. Lazarou, P-A. Guerne ........................................... 550

Articles

Longterm Effects of Rituximab on B Cell Counts and Autoantibody Production in RA: Use of High-sensitivity Flow Cytometry for More Sensitive Assessment of B Cell Depletion
A. Váncsa, Z. Szabó, S. Szamosi, et al ............................... 565

Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial

Efficacy and Safety of Belimumab in Patients with RA: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
W. Stohl, J.T. Merrill, J.D. McKay, et al ............................... 579

Evaluation of Serum Biomarkers Associated with Radiographic Progression in MTX-naive RA Patients Treated with MTX or Golimumab

Safety of Rituximab in Combination with Other Biologic DMARD in RA: An Open-label Study
W.F.C. Rigby, P.J. Mease, E. Olech, M. Ashby, S. Tole .............................................................. 599

Longterm Outcomes and Treatment After Myocardial Infarction in Patients with RA
S.S. McCoy, C.S. Crowson, H. Maradit-Kremers, et al ............................... 605

Trends in Serious Infections in RA
O.M. Ni Mhuircheartaigh, E.L. Matteson, A.B. Green, C.S. Crowson ..................................................... 611

Patterns and Associated Risk of Perioperative Use of Anti-TNF in Patients with RA Undergoing Total Knee Replacement

Early Local Swelling and Tenderness Are Associated with Large-joint Damage After 8 Years of Treatment to Target in Patients with Recent-onset RA
M. van den Broek, L. Dirven, H.M. Kroon, et al ............................... 624

Recomendations for Frequency of Visits to Monitor SLE in Asymptomatic Patients: Data from an Observational Cohort Study
D.D. Gladman, D. Ibañez, I. Ruiz, M.B. Urowitz ..................................................... 630

Progression of Nailfold Microvascular Damage and ANA Pattern in SSc
A. Sulli, B. Ruaro, V. Smith, et al ..................................................... 634

Mycophenolate Mofetil Improves Lung Function in CTD-associated ILD

Application and Modifications of Minimal Disease Activity Measures for Patients with PsA Treated with Adalimumab: Subanalyses of ADEPT
P.J. Mease, M. Heckaman, S. Kary, H. Kupper ............................... 647

Periarticular Bone Gain at PIP Joints and Changes in Bone Turnover Markers in Response to TNF Inhibitors in Rheumatoid and Psoriatic Arthritis
A. Szentpetery, M.J. McKenna, B.F. Murray, et al ............................... 653

Gene Expression of Catalytic Proteasome Subunits and Resistance Toward Proteasome Inhibition of B Lymphocytes from Patients with Primary SS

Urinary Biomarkers in Relapsing ANCA-associated Vasculitis

Free online via JRheum Full Release option

Contents continued opposite inside back cover .

PRINTED IN CANADA – ISSN 0315-162X
Downloaded on September 29, 2021 from www.jrheum.org
RANKL/OPG Ratio and DKK-1 Expression in Primary Osteoblastic Cultures from Osteoarthritic and Osteoporotic Subjects A. Corrado, A. Neve, A. Macchiarola, A. Gaudio, A. Marucci, F.P. Cantatore ................................. 684


Priming Primary Care Physicians to Treat Osteoporosis After a Fragility Fracture: An Integrated Multidisciplinary Approach S. Roux, M. Beaulieu, M-C. Beaulieu, F. Cabana, G. Boire .............................................. 703

Pathogen-specific Risk of ReA from Bacterial Causes of Foodborne Illness C.K. Porter, D. Choi, M.S. Riddle ........................................... 712

Pediatric Rheumatology

Disease Course, Outcome, and Predictors of Outcome in a Population-based JCA Cohort Followed for 17 Years L. Bertilsson, B. Andersson-Gäre, A. Fasth, I.F. Petersson, H. Forsblad-D’Elia ...................................................... 715

HLA-B27 Predicts a More Chronic Disease Course in an 8-year Followup Cohort of Patients with JIA L. Berntson, E. Nordal, K. Aalto, et al, for the Nordic Study Group of Paediatric Rheumatology ........................ 725

Correspondence

Five-Year Data from the REFLEX Study: A Different Interpretation A.M. Abeles ............................................................... 732


SLEDAI 2000 Responder Index-50 Website Z. Touma, M.B. Urowitz, D.D. Gladman ......................................................... 733

Reply D.A. Isenberg ................................................................. 734

Letters

Cutaneous Manifestations and Comorbidities in 60 Cases of Takayasu Arteritis L.K. Rocha, R. Romitti, S. Shinjo, M.L. Neto, J. Carvalho, P. Ciato. ................................................................. 734

Rapid Interaction Between CTLA4-Ig (Abatacept) and Synovial Macrophages from Patients with RA R. Brizzolara, P. Montagna, S. Soldano, M. Cutolo ........................................ 738

Decreased Expression of NAMPT in Patients with Juvenile Idiopathic Arthritis Receiving MTX E.J. Fox, J.S. Leeder, S.Q. Ye, M.L. Becker ........................................... 741

Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome P.J. Kahn, R.Q. Cron ................................................................. 743

Severe Vocal Cord Dysfunction: An Unusual Complication of Juvenile Dermatomyositis H.O. Althagafi, K. Morishita, R.E. Petty ............................................. 744


Correction

Lighting up the Genetic Understanding of Fibromyalgia H. Oren, J.N. Ablin ................................................................. 747

Meetings in Rheumatology .................................................. x